These parameters not only directly affect CD8+ T cell responses, but also likely affect other cell types that inhibit tumor killing, and thus in combination may create different in vivo biological contexts during antitumor therapy, leading to discrepant cancer therapy outcomes. Here, CD8A is linked to neoplasm.